Dr Kar, the board-certified interventional cardiologist
Peijia Medical has announced that Dr (Prof) Saibal Kar, the board-certified interventional cardiologist, has agreed to become the exclusive consultant in China to advise the research and development of the Mitral Transcatheter Edge to Edge Repair project (Peijia TEER, or Project Gemini) and to advise the Company in general.
Dr Kar is a world-leading doctor well-known for his research and achievement in the field of structured heart therapies, particularly in mitral repair space and the winner of several high calibre awards including Man of the Year Award by Centric Health Group. Dr Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA. He is recognised as the leading physician in developing and implementing minimally invasive techniques in structural heart disease interventions. Dr Kar has taught and mentored many physicians all around the world and was instrumental in helping China’s transcatheter heart valve repair/replacement development in the past. Dr Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
“With the exclusive service from Dr Kar, we can better understand the latest development in advanced structural heart interventions, improve Peijia’s market-leading innovative products, and accelerate market access of best-in-class minimally invasive technologies,” said Dr Yi Zhang, Chairman and Chief Executive Officer, Peijia. “By working directly with world-class KOLs like Dr Kar, our team will have the unique opportunity to be at the forefront of structural heart interventions, which will better position Peijia as a global innovation company.” Dr Kar will also advise Peijia’s R&D, Clinical, Business Development, etc.
Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020.
